Vaccination against c-herpesviruses has proved difficult. CD4 + T cells are essential to contain infection, but how best to prime them and whether this can reduce viral loads remain unclear. To address these questions, we used ovalbumin (OVA) as a model antigen, delivering it with murine cytomegalovirus (MCMV) to protect mice against OVA-expressing murine herpesvirus-4 (MuHV-4). Membrane-associated OVA (mOVA) was more effective than soluble OVA, both to prime CD4 + T cells and as an effector target. It was also a better target than an OVA epitope limited to infected cells, suggesting that protective CD4 + T cells recognize infected cell debris rather than infected cells themselves. While MCMV-mOVA protected acutely against MuHV-4-mOVA, long-term protection was incomplete, even when OVAspecific CD8 + T cells and B cells were also primed. Thus, even optimized single-target vaccines may poorly reduce long-term c-herpesvirus infections.
OVA expression by MCMV and MuHV-4 in vivoMCMV-OVA and MCMV-mOVA were attenuated for replication in vivo, after either intranasal (i.n.; Figure 2a) or intraperitoneal (i.p.; Figure 2b) inoculation, as described for similar IE2 disruptions. 29 The attenuation was less marked after i.p. infection, so we used this for immunization. MCMV-mOVA induced readily detectable OVA-specific IgG 2a -although little IgG 1 (Figure 2c). MCMV-OVA also induced OVA-specific antibody, but 333 J Yunis et al.CD4 + T cell vaccination
SUPPORTING INFORMATIONAdditional supporting information may be found online in the Supporting Information section at the end of the article.